STOCK TITAN

Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis

IRWD NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
63 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+26.7% close of January 2, 2026
1-year change
+43.3% closing prices, November 13, 2025 to November 13, 2026
1-month change
+34.5% closing prices, October 13, 2026 to November 13, 2026

Company Description

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) is a biotechnology company focused on developing and commercializing therapies for people living with gastrointestinal (GI) and rare diseases. The company’s work centers on conditions that can significantly affect quality of life, such as irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), functional constipation in children, and short bowel syndrome with intestinal failure (SBS-IF). Ironwood trades on the Nasdaq Global Select Market under the symbol IRWD and operates within the pharmaceutical preparation manufacturing industry.

According to the company, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), which it describes as the U.S. branded prescription market leader for adults with IBS-C or CIC. LINZESS is a once-daily capsule indicated for IBS-C and CIC in adults and for functional constipation in pediatric patients 6 to 17 years of age. It is not classified as a laxative; instead, it is the first medicine approved by the U.S. Food and Drug Administration (FDA) in a class called GC-C agonists, reflecting its mechanism of action on the guanylate cyclase-C receptor in the intestine. In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS, and linaclotide is also marketed by partners in Europe, Japan, China and other territories under various brand names.

Beyond its established GI franchise, Ironwood is advancing apraglutide, described by the company as a next-generation, long-acting synthetic GLP-2 analog. Apraglutide is being developed for short bowel syndrome (SBS) patients who are dependent on parenteral support, a severe chronic malabsorptive condition. Ironwood reports that apraglutide has generated strong safety and efficacy data in the STARS Phase 3 trial and in the STARS Extend long-term extension study, where multiple apraglutide-dosed patients achieved enteral autonomy, which the company characterizes as the ultimate goal for these patients. Following feedback from the FDA, Ironwood is working on a confirmatory Phase 3 trial design for SBS-IF and views apraglutide as a core part of its rare disease strategy.

Ironwood’s business model combines internal drug development with global collaborations. For LINZESS in the U.S., AbbVie provides U.S. net sales figures and the two companies share equally in U.S. brand collaboration profits. Outside the U.S., AbbVie markets linaclotide as CONSTELLA® in Europe for adults with moderate to severe IBS-C, Astellas markets linaclotide in Japan for adults with IBS-C or CIC, and AstraZeneca is a partner for development and commercialization in China. Ironwood’s revenues are closely tied to its share of net profits from LINZESS sales in the U.S., along with royalties and other collaboration-related income.

The company has highlighted LINZESS prescription demand growth over multiple reporting periods, based on IQVIA data, and has discussed commercial margin and collaboration revenue associated with the brand. At the same time, Ironwood has emphasized disciplined expense management, restructuring efforts, and adjusted EBITDA as key financial metrics. In public communications, Ironwood has described initiatives to streamline operations, reduce operating expenses, and focus resources on its GI and rare disease priorities, particularly LINZESS and apraglutide.

From a regulatory and corporate governance perspective, Ironwood files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 10-K, 10-Q and 8-K. SEC filings in 2025 reference matters such as changes in the company’s independent registered public accounting firm, material weaknesses in internal control over financial reporting as of December 31, 2024, Nasdaq notifications regarding bid price compliance, and a Nasdaq notice related to a delayed Form 10-K filing. The company has also disclosed engagement of financial advisors to explore strategic alternatives, which it describes as an effort to maximize stockholder or shareholder value.

Ironwood was founded in 1998 and is headquartered in Boston, Massachusetts, with an additional site in Basel, Switzerland. Across its communications, the company states that it keeps patients at the heart of its research and development and commercialization efforts, with the goal of reducing the burden of disease and addressing significant unmet needs in GI and rare disease populations.

Key therapeutic focus areas

  • Irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years and older, through LINZESS.
  • Chronic idiopathic constipation (CIC) in adults, treated with LINZESS.
  • Functional constipation in children and adolescents 6 to 17 years of age, for which LINZESS is approved.
  • Short bowel syndrome with intestinal failure (SBS-IF) in adults dependent on parenteral support, targeted by apraglutide.

Collaborations and geographic reach

  • Co-development and co-commercialization of LINZESS in the United States with AbbVie.
  • Marketing of linaclotide as CONSTELLA in Europe by AbbVie for adults with moderate to severe IBS-C.
  • Marketing of linaclotide in Japan by Astellas for adults with IBS-C or CIC.
  • Partnership with AstraZeneca for development and commercialization of LINZESS in China, and with AbbVie for linaclotide in other territories worldwide.

Regulatory and listing status

  • Ironwood’s Class A common stock trades on the Nasdaq Global Select Market under the symbol IRWD.
  • SEC Form 8-K filings in 2025 confirm continued listing on Nasdaq, including a notice of regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).
  • An 8-K dated March 27, 2025 notes a Nasdaq non-compliance notification related to a delayed Form 10-K filing, which the company stated it planned to address by filing as soon as practicable.

Risk and safety considerations

Because Ironwood’s marketed and investigational products address serious GI and rare diseases, safety and regulatory labeling are central to its operations. Public materials for LINZESS include a boxed warning regarding the risk of serious dehydration in pediatric patients less than 2 years of age, contraindications in patients under 2 years old and in patients with known or suspected mechanical gastrointestinal obstruction, and information on common adverse reactions such as diarrhea, abdominal pain, flatulence and abdominal distension in adults, and diarrhea in pediatric patients.

Stock Performance

$4.81
-0.41%
-0.02
After hoursChange vs the $4.83 closeLast updated: November 13, 2026 at 19:47
+43.3%
Performance 1 year
$796.3M

Ironwood Pharmaceuticals (IRWD) closed at $4.83 on November 13, 2026. Over the past 12 months, the price has gained 43.3%.

See what a $1,000 investment in IRWD would be worth today

Average down calculator for IRWD

IRWD Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Ironwood Pharmaceuticals has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include fda approval, earnings. View all IRWD news →

Financial Highlights

Ironwood Pharmaceuticals generated $296.2M in revenue in FY2025, operating income reached $98.5M (33.3% operating margin), and net income was $24.0M, reflecting a 8.1% net profit margin. Diluted earnings per share stood at $0.15. The company generated $127.0M in operating cash flow. The current ratio was 1.13, measuring current assets divided by current liabilities.

$296.2M
Revenue (FY2025)
$24.0M
Net Income (FY2025)
$127.0M
Operating Cash Flow

Upcoming Events

JAN
01
January 1, 2027 Corporate

CEO appointment

Tammi Gaskins to become Ironwood Pharmaceuticals CEO and board member effective 2027-01-01; Tom McCourt retires as CEO and stays on board.
YEAR
2029
2029 Regulatory

Regulatory filing planned

Ironwood plans a 2029 regulatory filing for apraglutide based on STARS-2 confirmatory Phase 3 trial results.

Ironwood Pharmaceuticals has 2 upcoming scheduled events. The next event, "CEO appointment", is scheduled for January 1, 2027 (in 47 days). Investors can track these dates to stay informed about potential catalysts that may affect the IRWD stock price.

Short Interest History

Last 12 Months

Short interest in Ironwood Pharmaceuticals (IRWD) currently stands at 14.9 million shares, down 6.5% from the previous reporting period, representing 9.3% of the float. Since November 2025, short interest has increased by 99.1%.

Days to Cover History

Last 12 Months

Days to cover for Ironwood Pharmaceuticals (IRWD) currently stands at 9.8 days, up 23.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 257.8%. Across the settlements charted above, it has ranged from 1.0 to 13.1 days.

IRWD Company Profile & Sector Positioning

Ironwood Pharmaceuticals (IRWD) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing IRWD often look at related companies in the same sector, including Collegium Pharmaceutical, Inc. (COLL), Evotec SE (EVO), Harrow, Inc. (HROW), Amphastar Pharmaceuticals, Inc. (AMPH), and Aquestive Therapeutics, Inc. (AQST). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate IRWD's relative position within its industry.

Frequently Asked Questions

The current stock price of Ironwood Pharmaceuticals (IRWD) is $4.81 in after-hours trading as of November 13, 2026.

The market cap of Ironwood Pharmaceuticals (IRWD) is approximately $796.3M. Learn more about what market capitalization means .

The FY2025 revenue of Ironwood Pharmaceuticals (IRWD) is $296.2M, from its most recent completed fiscal year.

The FY2025 net income of Ironwood Pharmaceuticals (IRWD) is $24.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Ironwood Pharmaceuticals (IRWD) is $0.15 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Ironwood Pharmaceuticals (IRWD) is $127.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Ironwood Pharmaceuticals (IRWD) is 8.1% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Ironwood Pharmaceuticals (IRWD) is 33.3% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The current ratio of Ironwood Pharmaceuticals (IRWD), current assets divided by current liabilities, was 1.13 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Ironwood Pharmaceuticals (IRWD) is $98.5M for FY2025, its most recent completed fiscal year. Learn about operating income.

Ironwood Pharmaceuticals is a biotechnology company that develops and commercializes therapies for people living with gastrointestinal (GI) and rare diseases. Its activities include the development and commercialization of LINZESS (linaclotide) for irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and functional constipation in certain pediatric patients, as well as the development of apraglutide, a long-acting synthetic GLP-2 analog for short bowel syndrome patients dependent on parenteral support.

Ironwood highlights two key assets. LINZESS (linaclotide) is a once-daily capsule indicated for adults with IBS-C or chronic idiopathic constipation and for functional constipation in children and adolescents 6 to 17 years of age. The company also is advancing apraglutide, described as a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support.

In the United States, LINZESS U.S. net sales are provided to Ironwood by its partner AbbVie. Ironwood and AbbVie share equally in U.S. brand collaboration profits, and Ironwood records collaboration revenue related to its share of net profits from LINZESS sales in the U.S. Outside the U.S., Ironwood receives royalties and other revenue associated with linaclotide through its partners.

Ironwood focuses on gastrointestinal and rare diseases. Its marketed product LINZESS addresses irritable bowel syndrome with constipation, chronic idiopathic constipation and functional constipation in pediatric patients. Its investigational program apraglutide targets short bowel syndrome with intestinal failure in patients who are dependent on parenteral support.

Ironwood Pharmaceuticals states that it was founded in 1998 and is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

Apraglutide is described by Ironwood as a once-weekly, long-acting synthetic glucagon-like peptide-2 (GLP-2) analog. It is being developed for adult short bowel syndrome patients with intestinal failure who are dependent on parenteral support. Ironwood reports that apraglutide has generated strong safety and efficacy data in the STARS Phase 3 trial and in the STARS Extend long-term extension study.

Ironwood describes LINZESS as the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation or chronic idiopathic constipation, based on IQVIA data. The company also notes that LINZESS is approved for functional constipation in pediatric patients 6 to 17 years of age.

Ironwood Pharmaceuticals’ Class A common stock is listed on the Nasdaq Global Select Market under the ticker symbol IRWD, as indicated in multiple SEC Form 8-K filings.

In 2025, Ironwood disclosed a Nasdaq non-compliance notification related to a delayed filing of its Annual Report on Form 10-K for the year ended December 31, 2024, and a separate notice regarding non-compliance with the minimum bid price requirement. An 8-K dated August 29, 2025 states that the company subsequently regained compliance with the minimum bid price rule after its common stock maintained a closing bid price of at least $1.00 per share for the required period.

Public materials for LINZESS include a boxed warning about the risk of serious dehydration in pediatric patients less than 2 years of age, and state that LINZESS is contraindicated in patients under 2 years old and in patients with known or suspected mechanical gastrointestinal obstruction. Diarrhea is described as the most common adverse reaction in adults with IBS-C or CIC and in pediatric patients treated for functional constipation, with additional common reactions in adults including abdominal pain, flatulence and abdominal distension.

Yes. In several 2025 communications, Ironwood states that it has engaged Goldman Sachs & Co. LLC to explore strategic alternatives for the company, which it characterizes as an effort to maximize stockholder or shareholder value. The company has indicated that this review is ongoing and that it plans to provide updates as appropriate.